Target type: biologicalprocess
Reactions triggered in response to the presence of a protozoan that act to protect the cell or organism. [GOC:jl]
Defense response to protozoan is a complex and multi-layered process involving both innate and adaptive immune mechanisms. The innate immune system provides the first line of defense against protozoan parasites. This involves recognition of pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs) on immune cells. PRRs can be located on the cell surface, within endosomes, or in the cytoplasm of immune cells. These receptors recognize molecules unique to protozoans, such as glycoproteins, lipophosphoglycans, and DNA. This recognition triggers signaling cascades that lead to the activation of immune cells and the production of inflammatory cytokines, such as TNF-α, IL-1β, and IL-6. These cytokines attract other immune cells to the site of infection and activate other immune cells. In addition to cytokine production, innate immune cells can directly kill protozoan parasites through phagocytosis, a process where the cell engulfs and destroys the parasite. Some protozoans have developed mechanisms to evade innate immune responses, such as forming cysts or altering their surface antigens. Adaptive immune responses are triggered when the innate immune system fails to contain the infection. Adaptive immunity involves the production of antigen-specific antibodies and cytotoxic T lymphocytes (CTLs). Antibodies produced by B lymphocytes specifically bind to antigens on the surface of protozoan parasites. This binding can directly neutralize the parasites, or can facilitate phagocytosis by macrophages. CTLs, on the other hand, directly kill protozoan-infected cells. The development of effective vaccines against protozoan parasites is challenging due to the complex life cycles, the ability of some parasites to evade the immune system, and the high mutation rates of some parasites. However, there are vaccines available for certain protozoan infections, such as malaria, and ongoing research is focused on developing new vaccines for other protozoan infections. Overall, defense response to protozoan is a crucial component of the host’s ability to combat these parasites. It is a complex and dynamic process involving multiple immune cells and signaling pathways. Understanding this response is essential for developing effective treatments and vaccines against protozoan infections.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Interleukin-10 | An interleukin-10 that is encoded in the genome of human. [PRO:JAN, UniProtKB:P22301] | Homo sapiens (human) |
| Arginase-1 | An arginase-1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P05089] | Homo sapiens (human) |
| GTPase HRas | A GTPase HRas that is encoded in the genome of human. [PRO:DNx, UniProtKB:P01112] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| stallimycin | |||
| 2-aminoimidazole | 2-aminoimidazole: from catabolism of arginine | ||
| n(omega)-hydroxyarginine | N(5)-[(Z)-amino(hydroxyimino)methyl]-L-ornithine : An N(5)-[amino(hydroxyimino)methyl]-L-ornithine in which the double bond has Z-configuration. N(omega)-hydroxyarginine: can cause vasorelaxation of bovine intrapulmonary artery; structure given in first source | amino acid zwitterion; N(5)-[(E)-amino(hydroxyimino)methyl]ornithine; N(5)-[(hydroxyamino)(imino)methyl]ornithine; N(5)-[(Z)-amino(hydroxyimino)methyl]ornithine; N(5)-[amino(hydroxyimino)methyl]-L-ornithine; N(5)-[amino(hydroxyimino)methyl]ornithine; N(omega)-hydroxy-L-arginine | |
| lonafarnib | lonafarnib : A 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide that has R configuration. It is used as oral farnesyltransferase inhibitor. lonafarnib: inhibitor of farnesyl protein transferase | 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide | antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor |
| l 778,123 | L-778,123 (free base) : A member of the class of imidazoles that is 1H-imidazole substituted by (4-cyanophenyl)methyl and [4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl groups at positions 1 and 5, respectively. It is a dual inhibitor of FPTase and GGPTase-I. | imidazoles; monochlorobenzenes; nitrile; piperazinone; tertiary amino compound | antineoplastic agent; EC 2.5.1.58 (protein farnesyltransferase) inhibitor; EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor |
| Nomega-hydroxy-nor-l-arginine | L-alpha-amino acid | ||
| bms 214662 | 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: a farnesyltransferase inhibitor; structure in first source BMS-214662 : A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors. | benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes | antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor |
| 3,3',4,5'-tetrahydroxystilbene | 3,3',4,5'-tetrahydroxystilbene: demethyl derivative of isorhapontigenin; structure in first source; a Syk kinase inhibitor; found in heartwood of FABACEAE; inhibitor of photosynthesis in spinach chloroplasts; may be inhibitor of plant growth; RN given refers to (E)-isomer piceatannol : A stilbenol that is trans-stilbene in which one of the phenyl groups is substituted by hydroxy groups at positions 3 and 4, while the other phenyl group is substituted by hydroxy groups at positions 3 and 5. | catechols; polyphenol; resorcinols; stilbenol | antineoplastic agent; apoptosis inducer; geroprotector; hypoglycemic agent; plant metabolite; protein kinase inhibitor; tyrosine kinase inhibitor |
| (S)-2-amino-6-boronohexanoic acid | (S)-2-amino-6-boronohexanoic acid : L-Norleucine substituted at C-6 with a borono group. | non-proteinogenic L-alpha-amino acid; organoboron compound | |
| 2-amino-6-boronohexanoic acid | |||
| hg-9-91-01 | HG-9-91-01 : A member of the class of phenylureas that is a potent inhibitor of salt-inducible kinase 2, a potential target protein for therapy in ovarian cancer. HG-9-91-01: inhibits salt-inducible kinases; structure in first source | aminopyrimidine; dimethoxybenzene; N-alkylpiperazine; N-arylpiperazine; phenylureas; secondary amino compound | antineoplastic agent; salt-inducible kinase 2 inhibitor |